Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glucagon-like peptide-1 + human transferrin
- Development stage
- Discontinued
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intraperitoneal, Subcutaneous
01
Overview
glucagon-like peptide-1 + human transferrin (BRX-0585) is a long-acting recombinant fusion protein consisting of a dipeptidyl peptidase-4 (DPP-4)-resistant glucagon-like peptide-1 (GLP-1) analog genetically fused to a non-glycosylated form of human transferrin. Developed by BioRexis Pharmaceutical (later acquired by Pfizer) in collaboration with the National Institute on Aging (NIA/NIH), this biologic is designed to overcome the extremely short half-life of native GLP-1 (1–2 minutes) by leveraging the transferrin receptor-mediated recycling pathway, extending its half-life to approximately 2 days. BRX-0585 acts as an agonist of the glucagon-like peptide 1 receptor (GLP-1R), stimulating glucose-dependent insulin secretion and promoting pancreatic beta-cell proliferation. It was investigated as a preclinical candidate for the treatment of type 2 diabetes mellitus and obesity.
- Other names
- BRX0585BRX-0585BRX 0585GLP-1-TfGLP1-TfGLP 1-TfGLP-1/hTfGLP-1/Tfglucagon-like peptide-1/human transferrin fusion protein
02
Targets
Beyond the preview
Go deeper on glucagon-like peptide-1 + human transferrin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glucagon-like peptide-1 + human transferrin.